HK1199617A1 - Compositions and methods for treating viral diseases - Google Patents

Compositions and methods for treating viral diseases

Info

Publication number
HK1199617A1
HK1199617A1 HK14113144.2A HK14113144A HK1199617A1 HK 1199617 A1 HK1199617 A1 HK 1199617A1 HK 14113144 A HK14113144 A HK 14113144A HK 1199617 A1 HK1199617 A1 HK 1199617A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
viral diseases
treating viral
treating
Prior art date
Application number
HK14113144.2A
Other languages
English (en)
Chinese (zh)
Inventor
Eliezer Huberman
Original Assignee
Novadrug Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novadrug Llc filed Critical Novadrug Llc
Publication of HK1199617A1 publication Critical patent/HK1199617A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK14113144.2A 2011-08-24 2014-12-31 Compositions and methods for treating viral diseases HK1199617A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526908P 2011-08-24 2011-08-24
PCT/US2012/052108 WO2013028890A1 (fr) 2011-08-24 2012-08-23 Compositions et procédés destinés au traitement de maladies virales

Publications (1)

Publication Number Publication Date
HK1199617A1 true HK1199617A1 (en) 2015-07-10

Family

ID=47746870

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14113144.2A HK1199617A1 (en) 2011-08-24 2014-12-31 Compositions and methods for treating viral diseases

Country Status (8)

Country Link
US (1) US9241930B2 (fr)
EP (1) EP2747765B1 (fr)
JP (1) JP6018206B2 (fr)
CN (1) CN103957911A (fr)
AU (1) AU2012298777B2 (fr)
CA (1) CA2846348C (fr)
HK (1) HK1199617A1 (fr)
WO (1) WO2013028890A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
WO2007124423A2 (fr) 2006-04-21 2007-11-01 Smithkline Beecham Corporation Antagonistes du récepteur de l'il-8
WO2008133669A2 (fr) 2006-12-14 2008-11-06 Gilead Sciences, Inc. Inhibiteurs viraux
CN101619064B (zh) 2008-07-01 2011-05-11 韶远化学科技（上海）有限公司 多氮杂环医药中间体的合成及工艺方法
WO2010014758A1 (fr) * 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Utilisation de pyrido[4,3-b]indoles hydrogénés pour le traitement du stress oxydatif
WO2010015815A2 (fr) * 2008-08-05 2010-02-11 Summit Corporation Plc Composés pour le traitement d'infections flavivirales
US9056099B2 (en) * 2010-03-01 2015-06-16 Novadrug, Llc Compositions and methods for treating viral diseases
JP2013522321A (ja) 2010-03-19 2013-06-13 パーデュー・リサーチ・ファウンデーション Ｈｉｖを治療するためのｃｃｒ５モジュレーター

Also Published As

Publication number Publication date
CN103957911A (zh) 2014-07-30
JP6018206B2 (ja) 2016-11-02
AU2012298777A1 (en) 2014-04-03
JP2014529611A (ja) 2014-11-13
WO2013028890A1 (fr) 2013-02-28
US9241930B2 (en) 2016-01-26
AU2012298777B2 (en) 2016-11-03
EP2747765A1 (fr) 2014-07-02
EP2747765B1 (fr) 2016-08-10
CA2846348A1 (fr) 2013-02-28
EP2747765A4 (fr) 2015-02-25
CA2846348C (fr) 2019-01-22
US20140249178A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
IL260585B (en) Preparations and methods for the treatment of diseases related to the retina of the eye
EP2684167A4 (fr) Compositions et méthodes utiles dans le traitement de maladies
HK1202416A1 (en) Compositions and methods for preventing and treating oral diseases
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
EP2655334A4 (fr) Compositions et méthodes utilisables en vue du traitement de maladies
SG11201402609RA (en) Compositions and methods for treating hepatitis c virus
EP2701742A4 (fr) Compositions et méthode de traitement de maladies auto-immunes
EP2771030A4 (fr) Compositions et méthodes de traitement de protéinopathies
EP2771341A4 (fr) Nouvelles compositions et procédés pour traiter le cancer
EP2773342A4 (fr) Compositions utiles pour le traitement de maladies virales
DK3292875T3 (en) Compositions and methods for treating diseases
ZA201404187B (en) Compositions and methods for treating dental conditions
EP2691529A4 (fr) Procédés et compositions pour traiter des maladies cérébrales
HK1202248A1 (en) Compositions and methods for treating neurodegenerative disease
HK1202246A1 (en) Compositions and methods for treating neurodegenerative disease
EP2802353A4 (fr) Compositions et méthodes de traitement d'infections virales
EP2663327A4 (fr) Compositions et méthodes de traitement d'infections virales
PL2604264T3 (pl) Kompozycja farmaceutyczna do leczenia chorób wirusowych
ZA201207226B (en) Compositions and methods for treating viral diseases
SG11201402899TA (en) Methods and compositions for treating viral diseases
EP2838903A4 (fr) Méthodes et compositions de traitement d'infections virales
HK1199617A1 (en) Compositions and methods for treating viral diseases
EP2718427A4 (fr) Compositions et procédés pour le traitement du glioblastome
IL232889A0 (en) Compounds and methods for treating hepatitis c virus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200819